Last updated on April 24, 2014 at 17:35 EDT

Heptares to Present at 5th CNS Partnering and Deal-Making Conference (13-14 SEPTEMBER)

September 12, 2012

WELWYN GARDEN CITY, England and BOSTON, September 12, 2012 /PRNewswire/ –

Heptares Therapeutics, the leading GPCR drug discovery company, announces that its
President, Dan Grau, will represent the Company at the 5th CNS Partnering and Deal-making
[http://www.gtcbio.com/component/conference/?file=home&cn=5th+CNS+Partnering+and+Deal-making&cid=38 ]
, which takes place at the Hilton San Francisco Financial District, San
Francisco, CA (13-14 September).

On 13 September, Mr Grau will be part of a panel discussion at 2:30pm (PST) entitled
“Partnering in the AD, PD and other Cognitive Disorders. How Have Things Changed?”

On 14 September, Mr Grau will give a presentation in the Licensing and Partnering
Strategies session at 10:15am (PST) entitled “Back to the Future in Neuroscience: A New
Approach to Old (and Validated) Targets.”

About Heptares Therapeutics

Heptares discovers and develops new medicines targeting GPCRs (G protein-coupled
receptors), a super-family of drug targets linked to a wide range of human diseases. Our
pharmaceutical partners include Shire, AstraZeneca, MedImmune and Takeda, and we have
raised $40M from MVM Life Science Partners, Clarus Ventures, Novartis Venture Fund and
Takeda Ventures.

Heptares is pioneering the application of structure-based drug design to the GPCR
superfamily of targets and is focused on creating molecules that modulate high-value, yet
historically undruggable or challenging, GPCRs. Our platform incorporates proprietary
technologies for engineering stabilised GPCRs in their natural pharmacological
conformations, identifying previously unknown chemistries for GPCR protein-drug
interactions, and deploying advanced fragment-based approaches to GPCR target space for
the first time.

Using this approach, we have generated a broad pipeline of drug candidates for the
treatment of serious disorders, including Alzheimer’s disease, Parkinson’s disease,
schizophrenia, depression, chronic insomnia, addiction disorders, and diabetes. For more
information about Heptares, please visit http://www.heptares.com.

SOURCE Heptares Therapeutics

Source: PR Newswire